GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (FRA:I5X) » Definitions » EV-to-FCF

Precigen (FRA:I5X) EV-to-FCF : -4.01 (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Precigen EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Precigen's Enterprise Value is €254.60 Mil. Precigen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-63.54 Mil. Therefore, Precigen's EV-to-FCF for today is -4.01.

The historical rank and industry rank for Precigen's EV-to-FCF or its related term are showing as below:

FRA:I5X' s EV-to-FCF Range Over the Past 10 Years
Min: -180.62   Med: -11.35   Max: 1268.18
Current: -4.28

During the past 13 years, the highest EV-to-FCF of Precigen was 1268.18. The lowest was -180.62. And the median was -11.35.

FRA:I5X's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.47 vs FRA:I5X: -4.28

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Precigen's stock price is €1.302. Precigen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.361. Therefore, Precigen's PE Ratio for today is At Loss.


Precigen EV-to-FCF Historical Data

The historical data trend for Precigen's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen EV-to-FCF Chart

Precigen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.45 -23.61 -13.46 -4.46 -4.06

Precigen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.46 -2.76 -2.84 -4.44 -4.06

Competitive Comparison of Precigen's EV-to-FCF

For the Biotechnology subindustry, Precigen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precigen's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Precigen's EV-to-FCF falls into.



Precigen EV-to-FCF Calculation

Precigen's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=254.603/-63.537
=-4.01

Precigen's current Enterprise Value is €254.60 Mil.
Precigen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-63.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Precigen  (FRA:I5X) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Precigen's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.302/-0.361
=At Loss

Precigen's share price for today is €1.302.
Precigen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.361.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Precigen EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Precigen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Precigen (FRA:I5X) Business Description

Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen (FRA:I5X) Headlines

No Headlines